Intuitive Surgical, Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. Intuitive develops, manufactures, and services the da Vinci surgical systems and Ion endoluminal system. It reports one operating segment.
Financial and operating performance
| Metric | FY2021 | FY2020 |
|---|---|---|
| Total revenue | $5.71 billion | $4.36 billion |
| Gross profit / margin | $3.96 billion / 69.3% | $2.86 billion / 65.6% |
| Operating income | $1.82 billion | $1.05 billion |
| Net income | $1.73 billion; $1.70 billion attributable to Intuitive | $1.07 billion; $1.06 billion attributable to Intuitive |
| Diluted earnings per share | $4.66 | $2.94 |
| Net cash from operating activities | $2.09 billion | $1.48 billion |
| Cash, cash equivalents, and investments | $8.62 billion | $6.87 billion |
| Total assets / total liabilities | $13.56 billion / $1.60 billion | $11.17 billion / $1.41 billion |
Product revenue was $4.79 billion and service revenue was $916 million. Recurring revenue— instruments and accessories, service, and operating leases—was $4.29 billion, or 75% of revenue. The filing does not present a separate debt balance; the balance sheet lists no borrowings. Current assets were $5.84 billion and current liabilities $1.15 billion at year-end.
- Systems revenue rose 44% to $1.69 billion; instruments and accessories revenue rose 26% to $3.10 billion; service revenue rose 27% to $916 million.
- Approximately 1.594 million da Vinci procedures were performed, up 28%. The installed base grew 12% to approximately 6,730 systems; placements rose 44% to 1,347. Utilization per system increased 17% from 2020.
- Cash used in investing activities was $2.46 billion, including $2.10 billion net purchases of investments and $354 million of capital expenditures. Financing activities provided $43 million; no shares were repurchased in 2021.
Changes versus the prior year
Revenue, operating income, and attributable net income rebounded from pandemic-affected 2020. Procedure volume recovered, but remained uneven across locations and specialties. Revenue growth reflected higher system placements, procedure-driven instrument sales, and a larger service base. The 2020 customer relief program reduced service revenue by $80 million; no similar program was offered in 2021.
Gross margin improved from 65.6% to 69.3%, supported by higher system average selling prices, lower excess and obsolete inventory costs, reduced intangible amortization, and the absence of abnormal low-production costs recorded in 2020. Higher share-based compensation partly offset these benefits. Interest and other income fell to $69 million from $157 million, primarily due to lower investment gains and interest income. The 2021 effective tax rate was 8.6%, including a one-time $66.4 million benefit from remeasurement of Swiss deferred tax assets.
Outlook, risks, and notable items
- Outlook: Management said it could not reliably estimate the pandemic’s effect on revenue in early 2022 and beyond. It expects 2022 capital expenditures of $700 million to $1 billion and substantial, increasing investment in research and development. It did not provide specific revenue or earnings guidance in the supplied filing text.
- COVID-19 and hospitals: Omicron-related hospitalizations and staffing shortages adversely affected procedure volumes in December 2021, particularly elective benign procedures, and the trend continued into January 2022. Deferred diagnoses and treatments may also weigh on future procedures; timing of recovery is uncertain.
- Supply and costs: Semiconductor and other component shortages, logistics constraints, inflation, and labor availability may raise costs or limit the ability to meet demand. Management said these had not materially affected deliveries or results to date, but warned that continued disruption could do so.
- Extended Use Program: Certain instruments shifted from 10 uses to 12–18 uses, with selected instrument price reductions. This lowers customer costs but reduces revenue per procedure; the future impact depends on procedure mix, volume, and market response.
- Regulatory and market risks: Growth depends on clearances, certifications, reimbursement, hospital capital budgets, and procedure adoption. China system sales remain subject to quota and hospital tender approvals; EU medical-device regulatory transition and competitive entry are also risks.
- Litigation: Product-liability suits and antitrust and patent matters remain pending. In an Ethicon stapler dispute, the USITC suspended any remedial order relating to certain SureForm products pending Federal Circuit review; a later order could restrict U.S. imports or require workarounds. The company could not estimate potential losses for several commercial litigation matters.
- Liquidity and commitments: The company reported $1.51 billion of purchase commitments and contractual obligations, $1.41 billion due within one year, and $182 million remaining on the deemed repatriation tax obligation. Management stated current liquidity and operating cash flows should meet foreseeable needs.
Investor verification priorities
- Track procedure growth, utilization, and system placements by geography, especially the effects of COVID-related staffing constraints and deferred care.
- Assess whether instrument revenue per procedure is being structurally reduced by Extended Use Instruments and related price changes.
- Monitor semiconductor and supplier availability, inflation, and the planned $700 million–$1 billion 2022 capital investment.
- Review the progress and financial exposure of the SureForm patent dispute, product-liability cases, and service-and-repair antitrust litigation.
- Check China quota and tender approvals, reimbursement developments, and EU regulatory certification timelines.
- Consider the sustainability of reported margins and the 8.6% tax rate, including the one-time Swiss tax benefit and share-based compensation tax effects.